María García‐Fortes
A5087494175- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Cutaneous lymphoproliferative disorders research
- Single-cell and spatial transcriptomics
- Histone Deacetylase Inhibitors Research
- Eosinophilic Disorders and Syndromes
- Neutropenia and Cancer Infections
- Kruppel-like factors research
- Insect Resistance and Genetics
- Clusterin in disease pathology
- Sepsis Diagnosis and Treatment
- Viral-associated cancers and disorders
- Protein Degradation and Inhibitors
- Hematopoietic Stem Cell Transplantation
- Ubiquitin and proteasome pathways
- Inflammatory Biomarkers in Disease Prognosis
- Fungal Infections and Studies
- Childhood Cancer Survivors' Quality of Life
- Cancer Treatment and Pharmacology
Hospital Clínico Universitario Virgen de la Victoria
2015-2025
Universidad de Málaga
2022
Hospital Universitario 12 De Octubre
2020
Promising results have been shown with the combination of ponatinib and chemotherapy in adults Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The PONALFIL (Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia) trial combined (30 mg/d) standard induction consolidation followed by allogeneic hematopoietic stem cell transplant (alloHSCT) newly diagnosed Ph+ ALL patients aged 18 to 60 years. Ponatinib was only given pre-emptively after...
The introduction of tyrosine kinase inhibitors (TKI) has significantly changed the outcome children and adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).1 Several phase 2 trials have shown improved outcomes incorporation ponatinib to first-line therapy, either in combination chemotherapy or blinatumomab,2-4 a matching adjusted indirect comparison versus imatinib as frontline treatment for Ph+ ALL showed significant survival advantage over containing...
This PETHEMA PCR-LMA study aimed to evaluate whether mutations detected by NGS (VAF cut-off of ≥5%) correlate with NPM1, FLT3-ITD, FLT3-TKD, IDH1, and IDH2 using conventional PCR (analytical sensitivity 3%) in a nationwide network seven reference laboratories. Between 2019 2021, 1685 adult AML patients at least one centralized sample (NGS or PCR) primary diagnosis relapse/refractory episode were included. During this period, 1288 paired NGS/PCR samples (1094 diagnosis, 103 relapse 88...
The effectiveness of venetoclax (VEN) in relapsed or refractory acute myeloid leukemia (RR-AML) has not been well established. This retrospective, multicenter, observational database studied the VEN a cohort 51 RR-AML patients and evaluated for predictors response overall survival (OS). median age was 68 years, most were at high risk, 61% received ≥2 therapies AML, 49% had hypomethylating agents, ECOG 52%. Complete remission (CR) rate, including CR with incomplete hematological recovery...
Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mortality require careful candidate selection. Therefore, accurate disease risk prognostication critical for treatment decision-making. We obtained registry data from patients diagnosed MF in 60 Spanish institutions (N = 1386). These were randomly divided into training set (80%) test (20%). A...
Abstract Background CPX‐351 is approved for the treatment of therapy related acute myeloid leukemia (t‐AML) and AML with myelodysplastic changes (MRC‐AML). The benefits this over standard chemotherapy has not been addressed in well matched cohorts real‐life patients. Methods Retrospective analysis patients treated as per routine practice. A propensity score matching (PSM) was used to compare their main outcomes those observed a cohort among 765 historical receiving intensive (IC), all them...
Available data have proved insufficient to develop consensus recommendations on the prevention of thrombosis and bleeding in myelofibrosis (MF). We evaluated incidence risk factors vascular complications 1613 patients from Spanish Myelofibrosis Registry. Over a total 6981 patient-years at risk, 6.4% study population had least one thrombotic event after MF diagnosis, amounting an rate 1.65 per 100 patient-years. Prior history thrombosis, JAK2 mutation, intermediate-2/high-risk International...
Clonal evolution in acute myeloid leukemia (AML) originates long before diagnosis and is a dynamic process that may affect survival. However, it remains uninvestigated during routine diagnostic workups. We hypothesized the mutational status of bone marrow dysplastic cells leukemic blasts, analyzed at onset AML using integrated multidimensional flow cytometry (MFC) immunophenotyping fluorescence-activated cell sorting (FACS) with next-generation sequencing (NGS), could reconstruct...
The comorbidity burden is an important risk factor for overall survival (OS) in several hematological malignancies. This observational prospective study was conducted to evaluate the impact of individual comorbidities on a multicenter series 668 patients with primary myelofibrosis (PMF) or MF secondary polycythemia vera (PPV-MF) essential thrombocythemia (PET-MF). Hypertension (hazard ratio (HR) = 4.96, p < 0.001), smoking (HR 5.08, dyslipidemia 4.65, 0.001) and hepatitis C virus (HCV) 4.26,...
This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval inhibitors. Most (63%) had received first-line intensive therapy + 7. Subsequently, salvage (n = 261), non-intensive 63) or supportive care only 80). Active (i.e., therapy) resulted a complete remission (CR) CR without hematological recovery (CRi) rate 42%....
Acute myeloid leukemia (AML), a hematologic malignancy that results in bone marrow failure, is the most common acute adults. The presence of FMS-related tyrosine kinase 3 (FLT3) mutations associated with poor prognosis, making evaluation FLT3-inhibitors an imperative goal clinical trials. Midostaurin was first FLT3-inhibitor approved by FDA and EMA for treatment FLT3-mutated AML, it showed significant improvement overall survival newly diagnosed patients treated midostaurin, combination...